1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Raily Aesthetic Medicine International Holdings Limited

Raily Aesthetic Medicine International Holdings Limited

HHKEX:2135
0.11
HKD
-0.01
(-7.08%)
86.41MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.24
0.34
0.4
0.42
0.39
0.34
1.97
0.37
0.34
- -
Basic EPS, GAAP
0.04
0.04
0.02
0.01
-0.04
-0.03
-0.34
-0.11
- -
- -
Free Cash Flow per Basic Share
0.07
0.04
0.01
0.01
-0.04
-0.04
-0.1
-0.07
0.04
- -
Dividend per Share
- -
0.03
0.04
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
0.03
0.2
0.39
0.37
0.35
0.29
0.19
0.19
0.19
Tangible Book Value per Share
-0.01
-0.01
0.15
0.34
0.17
0.16
0.14
0.1
0.11
0.11
Basic Weighted Avg Shares
473
473
473
395
480
481
96
533
557
557
Sales/Revenue/Turnover
113
159
191
165
188
165
189
199
189
- -
Operating Margin (%)
22.25
18.46
9.13
8.09
-10.24
-12.26
-11.87
-9.37
3.49
- -
Depreciation Expense
8
9
12
13
15
23
26
28
23
- -
Net Income, GAAP
17
18
10
4
-18
-16
-32
-59
2
- -
Effective Tax Rate (%)
25.4
30.19
37.29
57.54
- -
- -
- -
- -
22,070
- -
Profit Margin (%)
15.39
11.23
5.18
2.58
-9.39
-9.67
-17.14
-29.7
0.99
- -
Working Capital
-22
-38
23
120
36
36
-13
-33
-29
-29
LT Debt
12
21
20
14
40
35
34
27
10
10
Total Equity
16
15
93
187
182
166
133
96
98
98
Return on Invested Capital (%)
- -
43.83
11.18
3.24
- -
- -
- -
- -
-863.4
- -
Return on Capital (%)
- -
53.61
13.01
2.68
- -
- -
- -
- -
-386.55
- -
Return on Common Equity (%)
- -
114.01
18.31
3.05
-9.72
-9.24
-21.34
-48.89
1.77
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
30
54
49
LT Borrowings
3
1
- -
LT Finance Leases
23
17
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
557
557
557
Market Capitalization
56
64
78

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
90
83
97
Cash, Cash Equivalents & STI
29
36
58
Accounts Receivable, Net
2
1
2
Inventories
14
9
7
Total Current Liabilities
124
130
126
Payables & Accruals
- -
- -
- -
ST Debt
30
54
49
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-11.31%
2.87%
Free Cash Flow
- -
-68.58%
-163.77%
Net Income, GAAP
- -
-88.59%
-103.16%
Sales/Revenue/Turnover
- -
3.44%
-4.98%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
189
2024
- -
- -
199
2025
- -
- -
189

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.34
2024
- -
- -
-0.11
2025
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Liang Song
Full Time Employees
264
Sector
Health services
Industry
Medical/Nursing services
Address
Minhang Tower Hangzhou ZH China
IPO Date
Dec 28, 2020
Website
raily.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Raily Aesthetic Medicine International Holdings Limited is a Hong Kong-based company specializing in the research, development, manufacture, and sale of aesthetic medical products and services. Its core offerings include a wide range of aesthetic medicine devices, skincare products, and related medical consumables, focusing on innovative solutions for skin treatment, hair removal, body shaping, and anti-aging. The company operates primarily in the aesthetic medicine industry, targeting medical institutions, clinics, and beauty centers across Asia and other international markets. Founded in 2006, Raily is headquartered in Hong Kong and serves as a leading provider in the aesthetic medical field. Recently, Raily Aesthetic Medicine International Holdings Limited has strategically expanded its product portfolio with new launches in advanced aesthetic devices and skincare formulations, reinforcing its market presence. The company has also engaged in strategic partnerships and alliances in the last 1-2 years to enhance its innovation capabilities and broaden its distribution channels. Operationally, it has strengthened its manufacturing and R&D capabilities, positioning itself for sustained growth in the competitive aesthetic medicine sector. No major name changes or corporate reorganizations have been reported in the most recent period. Raily’s comprehensive product range includes professional aesthetic medical equipment, consumables such as laser handpieces and skincare products, and related technical services. Its strategic focus on innovation, customer-driven solutions, and geographic expansion across Asia-Pacific and selected global markets underscores its commitment to delivering high-quality aesthetic medical technologies and services.